Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

The Lancet Oncology in conversation with - A podcast by The Lancet Group

Categories:

Education

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma. Read the full Articles here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltex...